Page 76 - Read Online

psychoactive drugs increasing neurotransmitter 4. Sonn GA, Sadetsky N, Presti JC, Litwin MS. Differing perceptions of
concentrations shows an effect in CRF treatment. The quality of life in patients with prostate cancer and their doctors. J Urol
poor outcome of serotonergic drugs, as paroxetine and 2009;2:2296-302.
sertraline, on fatigue in randomized controlled trials 5. Saylor PJ, Smith MR. Metabolic complications of androgen deprivation
therapy for prostate cancer. J Urol 2009;181:1998-2006.
could be due to their selective action on the serotonin 6. Stone P, Hardy J, Huddart R, A’Hern R, Richards M. Fatigue in
reuptake. [13,16,19] Nevertheless, it is worth mentioning that patients with prostate cancer receiving hormone therapy. Eur J Cancer
a recent study stressed the role of tryptophan (a serotonin 2000;36:1134-41.
precursor) depletion in developing CRF and found a 7. Kyrdalen AE, Dahl AA, Hernes E, Hem E, Fossa SD. Fatigue in prostate
correlation between the higher degree of fatigue and cancer survivors treated with definitive radiotherapy and LHRH analogs.
lower tryptophan concentrations. Thus, a drug that acts 8. Prostate 2010;70:1480-9.
Capuron L, Miller AH. Immune system to brain signalling:
on more than one mechanism could be appropriate. [13] neuropsychopharmacological implications. Pharmacol Ther
Modafinil, a non-amphetamine psychostimulant, reduces 2011;130:226-38.
CRF intensity. Although the precise mechanism of 9. de la Cruz M, Hui D, Parsons HA, Bruera E. Placebo and nocebo effects
[12]
modafinil action has not been elucidated, it seems to in randomized double-blind clinical trials of agents for the therapy for
rely on the interaction of adrenergic and dopaminergic fatigue in patients with advanced cancer. Cancer 2010;116:766-74.
transmission in prefrontal cortices. Also, methylphenidate 10. Minton O, Richardson A, Sharpe M, Hotopf M, Stone P. A systematic
[20]
review and meta-analysis of the pharmacological treatment of cancer-
could facilitate excitatory synaptic signaling, mainly related fatigue. J Natl Cancer Inst 2008;20:1155-66.
through strengthening catecholaminergic synaptic 11. Nelson CJ, Mulhall JP, Roth AJ. The association between erectile
transmission. As a blocker of dopamine and norepinephrine dysfunction and depressive symptoms in men treated for prostate cancer.
transporters, it increases both extracellular dopamine and J Sex Med 2011;8:560-6.
norepinephrine. [21,22] 12. Carroll JK, Kohli S, Mustian KM, Roscoe JA, Morrow GR. Pharmacologic
treatment of cancer-related fatigue. Oncologist 2007;12:43-51.
Considering these data, the use of a drug like duloxetine, 13. Morrow GR, Hickok JT, Roscoe JA, Raubertas RF, Andrews PL,
Flynn PJ, Hynes HE, Banerjee TK, Kirshner JJ, King DK, University
that has a pleiotropic action on these pathways, has some of Rochester Cancer Center Community Clinical Oncology Program.
rationale in the treatment of CRF. Moreover, in our case, Differential effects of paroxetine on fatigue and depression: a
further benefit was derived from its activity on urinary randomized, double-blind trial from the University of Rochester
incontinence, thus promoting the patient’s sense of well- Cancer Center Community Clinical Oncology Program. J Clin Oncol
being and, therefore, ameliorating his quality of life and 2003;21:4635-41.
increasing his compliance with physical therapy (mild 14. Bellato E, Marini E, Castoldi F, Barbasetti N, Mattei L, Bonasia DE,
Blonna D. Fibromyalgia syndrome: etiology, pathogenesis, diagnosis and
exercise, daily walking), which has a therapeutic role in treatment. Pain Res Treat 2012;2012:426130.
CRF and in social life. 15. Knadler MP, Lobo E, Chappell J, Bergstrom R. Duloxetine: clinical
pharmacokinetics and drug interactions. Clin Pharmacokinet
In conclusion, a pilot placebo-controlled trial using 2011;50:281-94.
duloxetine seems worthwhile since it acts on fatigue, 16. Mease PJ. Further strategies for treating fibromyalgia: the role of serotonin
urinary symptoms and depression, all often occurring and norepinephrine reuptake inhibitors. Am J Med 2009;122:S44-55.
in a complex and multidimensional disease as prostate 17. Ahlberg K, Ekman T, Gaston-Johansson F, Mock V. Assessment
and management of cancer-related fatigue in adults. Lancet
cancer CRF. 2003;362:640-50.
18. Mottet N, Bastian PJ, Bellmunt J, van den Bergh RC, Bolla M, van
Financial support and sponsorship Casteren NJ, Cornford P, Joniau S, Mason MD, Matveev V, van der
Nil. Kwast TH, van der Poel H, Rouvière O, Wiegel T. Guidelines on Prostate
Cancer, European Association of Urology; 2014. Available from: http://
Conflicts of interest www.uroweb.org/wp-content/ uploads/1607-Prostate-Cancer_LRV3.pdf.
There are no conflicts of interest. [Last accessed on 2015 Aug 14].
19. Roscoe JA, Morrow GR, Hickok JT, Mustian KM, Griggs JJ, Matteson
SE, Bushunow P, Qazi R, Smith B. Effect of paroxetine hydrochloride
REFERENCES (Paxil) on fatigue and depression in breast cancer patients receiving
chemotherapy. Breast Cancer Res Treat 2005;89:243-9.
1. National Comprehensive Cancer Network Practice Guidelines. Cancer- 20. de Saint Hilaire Z, Orosco M, Rouch C, Blanc G, Nicolaidis S. Variations
related Fatigue Guidelines; 2014. Available from: http://www.nccn.org. in extracellular monoamines in the prefrontal cortex and medial
[Last accessed on 2014 Oct 18]. hypothalamus after modafinil administration: a microdialysis study in
2. Whitehead L. The measurement of fatigue in chronic illness: a systematic rats. Neuroreport 2001;12:3533-7.
review of unidimensional and multidimensional fatigue measures. J Pain 21. Kuczenski R, Segal DS. Effects of methylphenidate on extracellular
Symptom Manage 2009;37:107-28. dopamine, serotonin, and norepinephrine: comparison with amphetamine.
3. Meneses-Echávez JF, González-Jiménez E, Ramírez-Vélez R. Effects of J Neurochem 1997;68:2032-7.
supervised multimodal exercise interventions on cancer-related fatigue: 22. Gronier B. In vivo electrophysiological effects of methylphenidate in the
systematic review and meta-analysis of randomized controlled trials. prefrontal cortex: involvement of dopamine D1 and alpha 2 adrenergic
Biomed Res Int 2015;2015:328636. receptors. Eur Neuropsychopharmacol 2011;21:192-204.

66
Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ Issue 2 ¦ February 29, 2016 ¦